This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Health Policy  • Law and Medicine  • Alert me on articles by topic

Xavier Bosch, MD, PhD

JAMA. 2005;293:2202-2203.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Scientists in the United States who study human embryonic stem cells would find they have much in common with their counterparts in the European Union (EU), namely, highly polarized opinions on whether such work should be permitted and an equally divergent range of political support for funding it.

Federal funding in the United States is currently permitted only for research using a limited number of embryonic stem cell lines generated before 2001—cells that many scientists say are of poor quality—but generous funding is surfacing or being considered for stem cell research in some states. Similarly, the European Commission—the executive body responsible for EU-wide legislation—offers limited funding for stem cell research, but the EU’s 25 member nations are left to implement their own regulations. And because of these countries’ differing cultural and religious traditions, policies across Europe range from highly permissive to deeply restrictive, making a consensus . . . [Full Text of this Article]

CHANGING LEGISLATION